Ataibeckley depression drug delivers rapid day-2 antidepressant response

AtaiBeckley Inc. ATAI shares are up on Wednesday following the announcement of promising Phase 2a results for its ...

AtaiBeckley reports rapid response in Phase 2a trial of depression drug BPL-003

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) announced that patients in a mid-stage trial of its experimental depression ...

AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs

Day 2 following a single intranasal dose of BPL-003 in both the 10 mg (n=6) and 12 mg (n=6) cohorts; Durable responses ...

AtaiBeckley: 'Buy' On New Key Developments For BPL-003 For TRD

AtaiBeckley is well-capitalized with $220.7M in cash, sufficient to fund operations into 2029 and progress multiple TRD and ...
Nasdaq

atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

NEW YORK and BERLIN and OXFORD, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to ...

AtaiBeckley (ATAI) Reports 2025 Results and Q2 2026 Phase 3 Launch for BPL-003

AtaiBeckley Inc. (NASDAQ:ATAI) is one of the best new penny stocks to buy. On March 6, AtaiBeckley reported full-year 2025 ...

Deutsche Bank confident of AtaiBeckley Inc. (ATAI) growth prospects on psychedelic medicines

AtaiBeckley Inc. (NASDAQ:ATAI) is one of the best multibagger penny stocks to invest in. On March 27, Deutsche Bank initiated ...
Nasdaq

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

NEW YORK, and AMSTERDAM and OXFORD, United Kingdom, July 01, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company on a mission to develop ...
Bloomberg L.P.

Atai Shares Rise on Beckley’s Psychedelic Drug Study Success

Atai Life Sciences NV shares climbed after a psychedelic nasal spray from Beckley Psytech Ltd, the company it plans to acquire, significantly eased depression symptoms in a mid-stage trial. The study ...
Benzinga.com

Atai Life Sciences Experimental Depression Drug Shows Sustained Benefit In Treatment-Resistant Patients

Atai Life Sciences (NASDAQ:ATAI) and Beckley Psytech Limited, a private clinical-stage biopharmaceutical company, released data from a proof-of-concept study investigating a two-dose induction regimen ...
Seeking Alpha

atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First ...

ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of ...
Insider Monkey

Wall Street Bullish on AtaiBeckley (ATAI), Here’s Why

AtaiBeckley Inc. (NASDAQ:ATAI) is one of the Best Penny Stocks That Will Skyrocket. Wall Street is bullish on AtaiBeckley Inc. (NASDAQ:ATAI) with analysts’ 12-month median price target reflecting more ...